RxDoctor Payments Data

Karen Lauricella, NP

Nurse Practitioner · West Seneca, NYNPI 1962452722

Payments from drug & device makers

$8,964in general payments, 2019–2025

Across 407 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$926
  • Boehringer Ingelheim$917
  • Novo Nordisk$895
  • Amgen$793
  • Lilly USA, LLC$563
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,964 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$21,436
Medicare patients
119
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$45,902
EliquisApixaban57$42,522
OzempicSemaglutide35$37,808
JardianceEmpagliflozin34$35,314
MounjaroTirzepatide23$23,668
JanuviaSitagliptin Phosphate27$22,923
RybelsusSemaglutide13$16,263
XareltoRivaroxaban16$16,192
TrulicityDulaglutide15$15,965
MyrbetriqMirabegron16$10,363
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,735
Spiriva RespimatTiotropium Bromide17$8,709
Repatha SureclickEvolocumab11$8,543
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$6,801
Icosapent Ethyl17$5,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$895$54,07148 claims
GSKTrelegy Ellipta$926$45,90268 claims
Boehringer IngelheimJardiance, Spiriva Respimat$917$44,02351 claims
PfizerEliquis$263$42,52257 claims
Lilly USA, LLCMounjaro, Trulicity$563$39,63338 claims
MerckJanuvia$162$22,92327 claims
Johnson & JohnsonXarelto$56$16,19216 claims
Astellas Pharma US IncMyrbetriq$21$10,36316 claims
AstraZenecaBreztri Aerosphere$1,252$9,73516 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$4,152242 claims
AbbVieSynthroid$218$1,86841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in West Seneca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →